Table I.

Leading drug candidates by antiretroviral class

Antiretroviral Class	Leading Drug Candidate	Route of Administration	Phase of Development	FDA Approval
Capsid Inhibitors	GS-6207	Oral, subcutaneous injection	Ib	No
Maturation Inhibitor	GSK2838232	Oral	II	No
Nucleoside Reverse Transcriptase Translocation Inhibitors	Islatravir	Oral, subdermal implant	II	No
Anti-CD4 Monoclonal Antibodies	Ibalizumab	Infusion every 2 weeks	IV	Yes
Fusion Inhibitors	Albuvirtide	Intravenous injection	III	No
Non-Nucleoside Reverse Transcriptase Inhibitors	Elsulfavirine	Oral	II	No
Attachment Inhibitors	Fostemsavir	Oral	III	No